ID

DB08980||

名称

Fendiline

描述

Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.

cas号

13042-18-7

唯一标识码

S253D559A8

状态

solid

组

withdrawn,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
direct-parent:Diphenylmethanes
kingdom:Organic compounds
superclass:Benzenoids
class:Benzene and substituted derivatives
subclass:Diphenylmethanes
alternative-parent:Aralkylamines
alternative-parent:Dialkylamines
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organopnictogen compounds
substituent:Amine
substituent:Aralkylamine
substituent:Aromatic homomonocyclic compound
substituent:Diphenylmethane
substituent:Hydrocarbon derivative
substituent:Organic nitrogen compound
substituent:Organonitrogen compound
substituent:Organopnictogen compound
substituent:Secondary aliphatic amine
substituent:Secondary amine

消除途径

种类

Agents causing hyperkalemia

Amines
D000588
Antiarrhythmic agents
D000889
Bradycardia-Causing Agents

Calcium Channel Blockers
D002121
Calcium-Regulating Hormones and Agents
D000077264
Cardiovascular Agents
D002317
Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 Substrates

Ethylamines
D005021
Membrane Transport Modulators
D049990
Moderate Risk QTc-Prolonging Agents

Non-Selective Calcium Channel Blockers

Phenethylamines
D010627
Phenylalkylamine Derivatives

QTc Prolonging Agents

Vasodilating Agents
D014665

盐类

蛋白质结合

清除

同义词

国际品牌

配送量

产品

混合物

包装者

生产者

价格

受影响的生物体

剂量

form:Tablet
route:
strength:50 MG
form:Capsule
route:
strength:50 MG
form:Pill
route:
strength:50 MG

atc代码

Phenylalkylamine derivatives
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
CALCIUM CHANNEL BLOCKERS
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB09063
Fendiline may increase the bradycardic activities of Ceritinib.
DB09083
Fendiline may increase the bradycardic activities of Ivabradine.
DB08877
Ruxolitinib may increase the bradycardic activities of Fendiline.
DB00501
The serum concentration of Fendiline can be increased when it is combined with Cimetidine.
DB00758
The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline.
DB00625
The serum concentration of Fendiline can be decreased when it is combined with Efavirenz.
DB00252
The serum concentration of Phenytoin can be increased when it is combined with Fendiline.
DB01320
The serum concentration of Fosphenytoin can be increased when it is combined with Fendiline.
DB01065
The therapeutic efficacy of Fendiline can be decreased when used in combination with Melatonin.
DB00607
The therapeutic efficacy of Fendiline can be decreased when used in combination with Nafcillin.
DB00325
Fendiline may increase the hypotensive activities of Nitroprusside.
DB01219
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fendiline.
DB14507
The risk or severity of adverse effects can be increased when Fendiline is combined with Lithium citrate.
DB14509
The risk or severity of adverse effects can be increased when Fendiline is combined with Lithium carbonate.
DB14506
The risk or severity of adverse effects can be increased when Fendiline is combined with Lithium hydroxide.
DB08873
The serum concentration of Fendiline can be increased when it is combined with Boceprevir.
DB01056
Tocainide may increase the arrhythmogenic activities of Fendiline.
DB01429
Aprindine may increase the arrhythmogenic activities of Fendiline.
DB06694
Xylometazoline may increase the arrhythmogenic activities of Fendiline.
DB06727
Sparteine may increase the arrhythmogenic activities of Fendiline.
DB08162
Fasudil may increase the arrhythmogenic activities of Fendiline.
DB00521
Fendiline may increase the arrhythmogenic activities of Carteolol.
DB01214
Fendiline may increase the arrhythmogenic activities of Metipranolol.
DB11699
Fendiline may increase the arrhythmogenic activities of Tropisetron.
DB12704
Fendiline may increase the arrhythmogenic activities of Spiradoline.
DB13635
Fendiline may increase the arrhythmogenic activities of Tiracizine.
DB13645
Fendiline may increase the arrhythmogenic activities of Ethacizine.
DB13718
Fendiline may increase the arrhythmogenic activities of Hydroquinine.
DB13746
Fendiline may increase the arrhythmogenic activities of Bioallethrin.
DB13863
Fendiline may increase the arrhythmogenic activities of Fosfructose.
DB15300
Fendiline may increase the arrhythmogenic activities of Hydroquinidine.
DB15366
Fendiline may increase the arrhythmogenic activities of SOR-C13.
DB00390
Fendiline may increase the arrhythmogenic activities of Digoxin.
DB00511
Fendiline may increase the arrhythmogenic activities of Acetyldigitoxin.
DB01078
Fendiline may increase the arrhythmogenic activities of Deslanoside.
DB13240
Fendiline may increase the arrhythmogenic activities of Cymarin.
DB13401
Fendiline may increase the arrhythmogenic activities of Metildigoxin.
DB13691
Fendiline may increase the arrhythmogenic activities of Acetyldigoxin.
DB00280
Fendiline may increase the arrhythmogenic activities of Disopyramide.
DB00308
Fendiline may increase the arrhythmogenic activities of Ibutilide.
DB01035
Fendiline may increase the arrhythmogenic activities of Procainamide.
DB01244
Fendiline may increase the arrhythmogenic activities of Bepridil.
DB13725
Fendiline may increase the arrhythmogenic activities of Terodiline.
DB00343
Diltiazem may increase the arrhythmogenic activities of Fendiline.
DB00393
Nimodipine may increase the arrhythmogenic activities of Fendiline.
DB00568
Cinnarizine may increase the arrhythmogenic activities of Fendiline.
DB00572
Atropine may increase the arrhythmogenic activities of Fendiline.
DB00640
Adenosine may increase the arrhythmogenic activities of Fendiline.
DB00922
Levosimendan may increase the arrhythmogenic activities of Fendiline.
DB01115
Nifedipine may increase the arrhythmogenic activities of Fendiline.
DB01195
Flecainide may increase the arrhythmogenic activities of Fendiline.
DB04825
Prenylamine may increase the arrhythmogenic activities of Fendiline.
DB04842
Fluspirilene may increase the arrhythmogenic activities of Fendiline.
DB04957
Azimilide may increase the arrhythmogenic activities of Fendiline.
DB06200
Tedisamil may increase the arrhythmogenic activities of Fendiline.
DB06712
Nilvadipine may increase the arrhythmogenic activities of Fendiline.
DB08992
Fendiline may increase the arrhythmogenic activities of Eperisone.
DB09224
Fendiline may increase the arrhythmogenic activities of Melperone.
DB09231
Fendiline may increase the arrhythmogenic activities of Benidipine.
DB12286
Fendiline may increase the arrhythmogenic activities of Simendan.
DB13500
Fendiline may increase the arrhythmogenic activities of Otilonium.
DB13546
Fendiline may increase the arrhythmogenic activities of Nizofenone.
DB13652
Fendiline may increase the arrhythmogenic activities of Bunaftine.
DB13653
Fendiline may increase the arrhythmogenic activities of Lorcainide.
DB13791
Fendiline may increase the arrhythmogenic activities of Penfluridol.
DB14063
Fendiline may increase the arrhythmogenic activities of Dexverapamil.
DB00230
Pregabalin may increase the arrhythmogenic activities of Fendiline.
DB00270
Isradipine may increase the arrhythmogenic activities of Fendiline.
DB00347
Trimethadione may increase the arrhythmogenic activities of Fendiline.
DB00381
Amlodipine may increase the arrhythmogenic activities of Fendiline.
DB00424
Hyoscyamine may increase the arrhythmogenic activities of Fendiline.
DB00555
Lamotrigine may increase the arrhythmogenic activities of Fendiline.
DB00622
Nicardipine may increase the arrhythmogenic activities of Fendiline.
DB00661
Verapamil may increase the arrhythmogenic activities of Fendiline.
DB00678
Losartan may increase the arrhythmogenic activities of Fendiline.
DB00680
Moricizine may increase the arrhythmogenic activities of Fendiline.
DB00825
Levomenthol may increase the arrhythmogenic activities of Fendiline.
DB00909
Zonisamide may increase the arrhythmogenic activities of Fendiline.
DB01054
Nitrendipine may increase the arrhythmogenic activities of Fendiline.
DB01074
Perhexiline may increase the arrhythmogenic activities of Fendiline.
DB01158
Bretylium may increase the arrhythmogenic activities of Fendiline.
DB01228
Encainide may increase the arrhythmogenic activities of Fendiline.
DB01426
Ajmaline may increase the arrhythmogenic activities of Fendiline.
DB05246
Methsuximide may increase the arrhythmogenic activities of Fendiline.
DB06217
Vernakalant may increase the arrhythmogenic activities of Fendiline.
DB06283
Ziconotide may increase the arrhythmogenic activities of Fendiline.
DB06468
Cariporide may increase the arrhythmogenic activities of Fendiline.
DB09089
Trimebutine may increase the arrhythmogenic activities of Fendiline.
DB09090
Pinaverium may increase the arrhythmogenic activities of Fendiline.
DB09229
Aranidipine may increase the arrhythmogenic activities of Fendiline.
DB09235
Efonidipine may increase the arrhythmogenic activities of Fendiline.
DB09236
Lacidipine may increase the arrhythmogenic activities of Fendiline.
DB09239
Niguldipine may increase the arrhythmogenic activities of Fendiline.
DB12093
Tetrahydropalmatine may increase the arrhythmogenic activities of Fendiline.
DB12712
Pilsicainide may increase the arrhythmogenic activities of Fendiline.
DB12766
Cicletanine may increase the arrhythmogenic activities of Fendiline.
DB12923
Gallopamil may increase the arrhythmogenic activities of Fendiline.
DB13358
Cibenzoline may increase the arrhythmogenic activities of Fendiline.
DB13488
Bencyclane may increase the arrhythmogenic activities of Fendiline.
DB13555
Prajmaline may increase the arrhythmogenic activities of Fendiline.
DB13651
Lorajmine may increase the arrhythmogenic activities of Fendiline.
DB13766
Lidoflazine may increase the arrhythmogenic activities of Fendiline.
DB00528
Lercanidipine may increase the arrhythmogenic activities of Fendiline.
DB04743
Nimesulide may increase the arrhythmogenic activities of Fendiline.
DB04838
Cyclandelate may increase the arrhythmogenic activities of Fendiline.
DB04841
Flunarizine may increase the arrhythmogenic activities of Fendiline.
DB04920
Clevidipine may increase the arrhythmogenic activities of Fendiline.
DB05885
Seletracetam may increase the arrhythmogenic activities of Fendiline.
DB06152
Nylidrin may increase the arrhythmogenic activities of Fendiline.
DB06446
Dotarizine may increase the arrhythmogenic activities of Fendiline.
DB07615
Tranilast may increase the arrhythmogenic activities of Fendiline.
DB08838
Agmatine may increase the arrhythmogenic activities of Fendiline.
DB09216
Fendiline may increase the arrhythmogenic activities of Tolfenamic acid.
DB09220
Fendiline may increase the arrhythmogenic activities of Nicorandil.
DB09227
Fendiline may increase the arrhythmogenic activities of Barnidipine.
DB09230
Fendiline may increase the arrhythmogenic activities of Azelnidipine.
DB09232
Fendiline may increase the arrhythmogenic activities of Cilnidipine.
DB09234
Fendiline may increase the arrhythmogenic activities of Darodipine.
DB09238
Fendiline may increase the arrhythmogenic activities of Manidipine.
DB09240
Fendiline may increase the arrhythmogenic activities of Niludipine.
DB11960
Fendiline may increase the arrhythmogenic activities of Carboxyamidotriazole.
DB12092
Fendiline may increase the arrhythmogenic activities of Naftopidil.
DB12131
Fendiline may increase the arrhythmogenic activities of Vinpocetine.
DB13835
Fendiline may increase the arrhythmogenic activities of Caroverine.
DB13950
Fendiline may increase the arrhythmogenic activities of WIN 55212-2.
DB13961
Fendiline may increase the arrhythmogenic activities of Fish oil.
DB14064
Fendiline may increase the arrhythmogenic activities of Emopamil.
DB14065
Fendiline may increase the arrhythmogenic activities of Lomerizine.
DB14066
Fendiline may increase the arrhythmogenic activities of Tetrandrine.
DB14068
Fendiline may increase the arrhythmogenic activities of Dexniguldipine.
DB14207
Fendiline may increase the arrhythmogenic activities of Fosinoprilat.
DB00222
Fendiline may increase the arrhythmogenic activities of Glimepiride.
DB00204
Fendiline may increase the arrhythmogenic activities of Dofetilide.
DB00908
Fendiline may increase the arrhythmogenic activities of Quinidine.
DB04855
Fendiline may increase the arrhythmogenic activities of Dronedarone.
DB00836
Loperamide may increase the arrhythmogenic activities of Fendiline.
DB01388
Mibefradil may increase the arrhythmogenic activities of Fendiline.
DB00593
Ethosuximide may increase the arrhythmogenic activities of Fendiline.
DB01023
Felodipine may increase the arrhythmogenic activities of Fendiline.
DB01396
Digitoxin may increase the arrhythmogenic activities of Fendiline.
DB00401
Nisoldipine may increase the arrhythmogenic activities of Fendiline.
DB00281
Lidocaine may increase the arrhythmogenic activities of Fendiline.
DB00379
Mexiletine may increase the arrhythmogenic activities of Fendiline.
DB12212
Fendiline may increase the arrhythmogenic activities of Landiolol.
DB00264
The risk or severity of bradycardia can be increased when Fendiline is combined with Metoprolol.
DB00335
The risk or severity of bradycardia can be increased when Fendiline is combined with Atenolol.
DB00866
The risk or severity of bradycardia can be increased when Fendiline is combined with Alprenolol.
DB00960
The risk or severity of bradycardia can be increased when Fendiline is combined with Pindolol.
DB01203
The risk or severity of bradycardia can be increased when Fendiline is combined with Nadolol.
DB01297
The risk or severity of bradycardia can be increased when Fendiline is combined with Practolol.
DB01359
The risk or severity of bradycardia can be increased when Fendiline is combined with Penbutolol.
DB03322
The risk or severity of bradycardia can be increased when Fendiline is combined with Dexpropranolol.
DB04861
The risk or severity of bradycardia can be increased when Fendiline is combined with Nebivolol.
DB06726
The risk or severity of bradycardia can be increased when Fendiline is combined with Bufuralol.
DB08807
The risk or severity of bradycardia can be increased when Fendiline is combined with Bopindolol.
DB09351
The risk or severity of bradycardia can be increased when Fendiline is combined with Levobetaxolol.
DB13443
The risk or severity of bradycardia can be increased when Fendiline is combined with Esatenolol.
DB13508
The risk or severity of bradycardia can be increased when Fendiline is combined with Cloranolol.
DB13530
The risk or severity of bradycardia can be increased when Fendiline is combined with Mepindolol.
DB13757
The risk or severity of bradycardia can be increased when Fendiline is combined with Epanolol.
DB13775
The risk or severity of bradycardia can be increased when Fendiline is combined with Tertatolol.
DB00598
The risk or severity of bradycardia can be increased when Labetalol is combined with Fendiline.
DB01136
The risk or severity of bradycardia can be increased when Carvedilol is combined with Fendiline.
DB01295
The risk or severity of bradycardia can be increased when Bevantolol is combined with Fendiline.
DB12752
The risk or severity of bradycardia can be increased when Bucindolol is combined with Fendiline.
DB00489
The risk or severity of bradycardia can be increased when Fendiline is combined with Sotalol.
DB00195
The risk or severity of bradycardia can be increased when Betaxolol is combined with Fendiline.
DB00571
The risk or severity of bradycardia can be increased when Propranolol is combined with Fendiline.
DB01182
The risk or severity of bradycardia can be increased when Propafenone is combined with Fendiline.
DB01193
The risk or severity of bradycardia can be increased when Acebutolol is combined with Fendiline.
DB01580
The risk or severity of bradycardia can be increased when Oxprenolol is combined with Fendiline.
DB08952
The risk or severity of bradycardia can be increased when Indenolol is combined with Fendiline.
DB00187
The risk or severity of bradycardia can be increased when Esmolol is combined with Fendiline.
DB04846
The risk or severity of bradycardia can be increased when Celiprolol is combined with Fendiline.
DB08808
The risk or severity of bradycardia can be increased when Bupranolol is combined with Fendiline.
DB11770
The risk or severity of bradycardia can be increased when Talinolol is combined with Fendiline.
DB11785
The risk or severity of bradycardia can be increased when Anisodamine is combined with Fendiline.
DB01092
The serum concentration of Ouabain can be increased when it is combined with Fendiline.
DB12843
The serum concentration of Oleandrin can be increased when it is combined with Fendiline.
DB13307
The serum concentration of Proscillaridin can be increased when it is combined with Fendiline.
DB13467
The serum concentration of Lanatoside C can be increased when it is combined with Fendiline.
DB13537
The serum concentration of Gitoformate can be increased when it is combined with Fendiline.
DB13756
The serum concentration of Peruvoside can be increased when it is combined with Fendiline.
DB00199
The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Fendiline.
DB00241
The metabolism of Fendiline can be increased when combined with Butalbital.
DB00418
The metabolism of Fendiline can be increased when combined with Secobarbital.
DB00474
The metabolism of Fendiline can be increased when combined with Methohexital.
DB00599
The metabolism of Fendiline can be increased when combined with Thiopental.
DB00849
The metabolism of Fendiline can be increased when combined with Methylphenobarbital.
DB01154
The metabolism of Fendiline can be increased when combined with Thiamylal.
DB01351
The metabolism of Fendiline can be increased when combined with Amobarbital.
DB01355
The metabolism of Fendiline can be increased when combined with Hexobarbital.
DB01483
The metabolism of Fendiline can be increased when combined with Barbital.
DB09001
The metabolism of Fendiline can be increased when combined with Barbexaclone.
DB00312
The metabolism of Fendiline can be increased when combined with Pentobarbital.
DB00794
The metabolism of Fendiline can be increased when combined with Primidone.
DB01174
The metabolism of Fendiline can be increased when combined with Phenobarbital.
DB00237
The metabolism of Fendiline can be increased when combined with Butabarbital.
DB00258
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium acetate.
DB00326
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium glucoheptonate.
DB01164
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium chloride.
DB11126
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium gluconate.
DB13142
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium glubionate anhydrous.
DB13590
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium pangamate.
DB13800
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium levulinate.
DB14577
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium cation.
DB01373
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Fendiline.
DB00590
The risk or severity of hypotension can be increased when Doxazosin is combined with Fendiline.
DB00692
The risk or severity of hypotension can be increased when Phentolamine is combined with Fendiline.
DB00699
The risk or severity of hypotension can be increased when Nicergoline is combined with Fendiline.
DB00706
The risk or severity of hypotension can be increased when Tamsulosin is combined with Fendiline.
DB00777
The risk or severity of hypotension can be increased when Propiomazine is combined with Fendiline.
DB00797
The risk or severity of hypotension can be increased when Tolazoline is combined with Fendiline.
DB00831
The risk or severity of hypotension can be increased when Trifluoperazine is combined with Fendiline.
DB00925
The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fendiline.
DB01162
The risk or severity of hypotension can be increased when Terazosin is combined with Fendiline.
DB01608
The risk or severity of hypotension can be increased when Periciazine is combined with Fendiline.
DB01614
The risk or severity of hypotension can be increased when Acepromazine is combined with Fendiline.
DB01622
The risk or severity of hypotension can be increased when Thioproperazine is combined with Fendiline.
DB06153
The risk or severity of hypotension can be increased when Pizotifen is combined with Fendiline.
DB06207
The risk or severity of hypotension can be increased when Silodosin is combined with Fendiline.
DB08950
The risk or severity of hypotension can be increased when Indoramin is combined with Fendiline.
DB09128
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Fendiline.
DB09206
The risk or severity of hypotension can be increased when Trimazosin is combined with Fendiline.
DB12230
The risk or severity of hypotension can be increased when Bunazosin is combined with Fendiline.
DB12278
The risk or severity of hypotension can be increased when Propiverine is combined with Fendiline.
DB12661
The risk or severity of hypotension can be increased when Urapidil is combined with Fendiline.
DB00320
The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Fendiline.
DB00696
The risk or severity of hypotension can be increased when Ergotamine is combined with Fendiline.
DB01149
The risk or severity of hypotension can be increased when Nefazodone is combined with Fendiline.
DB01200
The risk or severity of hypotension can be increased when Bromocriptine is combined with Fendiline.
DB00416
Fendiline may increase the neuromuscular blocking activities of Metocurine iodide.
DB00483
Fendiline may increase the neuromuscular blocking activities of Gallamine triethiodide.
DB00565
Fendiline may increase the neuromuscular blocking activities of Cisatracurium.
DB00728
Fendiline may increase the neuromuscular blocking activities of Rocuronium.
DB00732
Fendiline may increase the neuromuscular blocking activities of Atracurium besylate.
DB01135
Fendiline may increase the neuromuscular blocking activities of Doxacurium.
DB01199
Fendiline may increase the neuromuscular blocking activities of Tubocurarine.
DB01226
Fendiline may increase the neuromuscular blocking activities of Mivacurium.
DB01336
Fendiline may increase the neuromuscular blocking activities of Metocurine.
DB01337
Fendiline may increase the neuromuscular blocking activities of Pancuronium.
DB01338
Fendiline may increase the neuromuscular blocking activities of Pipecuronium.
DB01339
Fendiline may increase the neuromuscular blocking activities of Vecuronium.
DB04834
Fendiline may increase the neuromuscular blocking activities of Rapacuronium.
DB13295
Fendiline may increase the neuromuscular blocking activities of Atracurium.
DB13584
Fendiline may increase the neuromuscular blocking activities of Gallamine.
DB13648
Fendiline may increase the neuromuscular blocking activities of Alcuronium.
DB00653
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium sulfate.
DB01377
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium oxide.
DB01397
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium salicylate.
DB08938
The risk or severity of hypotension can be increased when Fendiline is combined with Magaldrate.
DB09104
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium hydroxide.
DB09281
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium trisilicate.
DB09407
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium chloride.
DB09481
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium carbonate.
DB11110
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium citrate.
DB13249
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium silicate.
DB13322
The risk or severity of hypotension can be increased when Fendiline is combined with Hydrotalcite.
DB13359
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium aspartate.
DB13486
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium peroxide.
DB13749
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium gluconate.
DB13786
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium orotate.
DB14514
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium levulinate.
DB14515
The risk or severity of hypotension can be increased when Fendiline is combined with Magnesium lactate.
DB00215
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Citalopram.
DB00261
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Anagrelide.
DB00283
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Clemastine.
DB00313
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Valproic acid.
DB00365
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Grepafloxacin.
DB00468
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Quinine.
DB00530
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Erlotinib.
DB00539
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Toremifene.
DB00619
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Imatinib.
DB00679
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Thioridazine.
DB00685
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Trovafloxacin.
DB00834
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Mifepristone.
DB00875
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Flupentixol.
DB00907
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Cocaine.
DB01169
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Arsenic trioxide.
DB01175
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Escitalopram.
DB01184
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Domperidone.
DB01208
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Sparfloxacin.
DB01218
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Halofantrine.
DB01267
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Paliperidone.
DB01405
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Temafloxacin.
DB01624
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Zuclopenthixol.
DB04844
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Tetrabenazine.
DB04868
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Nilotinib.
DB04946
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Iloperidone.
DB05294
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Vandetanib.
DB06176
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Romidepsin.
DB06216
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Asenapine.
DB06697
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Artemether.
DB06708
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Lumefantrine.
DB08881
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Vemurafenib.
DB11730
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Ribociclib.
DB11978
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Glasdegib.
DB12161
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Deutetrabenazine.
DB13074
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Macimorelin.
DB00342
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Terfenadine.
DB00604
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Cisapride.
DB00637
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Astemizole.
DB01100
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Pimozide.
DB09039
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Eliglustat.
DB01356
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Lithium cation.
DB00007
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fendiline.
DB00014
The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fendiline.
DB00207
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fendiline.
DB00218
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fendiline.
DB00243
The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Fendiline.
DB00263
The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Fendiline.
DB00333
The risk or severity of QTc prolongation can be increased when Methadone is combined with Fendiline.
DB00363
The risk or severity of QTc prolongation can be increased when Clozapine is combined with Fendiline.
DB00391
The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Fendiline.
DB00420
The risk or severity of QTc prolongation can be increased when Promazine is combined with Fendiline.
DB00433
The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Fendiline.
DB00450
The risk or severity of QTc prolongation can be increased when Droperidol is combined with Fendiline.
DB00477
The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Fendiline.
DB00526
The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fendiline.
DB00537
The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fendiline.
DB00544
The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fendiline.
DB00556
The risk or severity of QTc prolongation can be increased when Perflutren is combined with Fendiline.
DB00608
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Fendiline.
DB00738
The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Fendiline.
DB00743
The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Fendiline.
DB00748
The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Fendiline.
DB00757
The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Fendiline.
DB00778
The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Fendiline.
DB00779
The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Fendiline.
DB00827
The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Fendiline.
DB00889
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Fendiline.
DB00904
The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Fendiline.
DB00933
The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Fendiline.
DB00967
The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Fendiline.
DB00978
The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Fendiline.
DB00985
The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Fendiline.
DB01087
The risk or severity of QTc prolongation can be increased when Primaquine is combined with Fendiline.
DB01113
The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fendiline.
DB01114
The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Fendiline.
DB01137
The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fendiline.
DB01155
The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Fendiline.
DB01165
The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Fendiline.
DB01599
The risk or severity of QTc prolongation can be increased when Probucol is combined with Fendiline.
DB01615
The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Fendiline.
DB02638
The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Fendiline.
DB04948
The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Fendiline.
DB05223
The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Fendiline.
DB05488
The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Fendiline.
DB06160
The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Fendiline.
DB06334
The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Fendiline.
DB06402
The risk or severity of QTc prolongation can be increased when Telavancin is combined with Fendiline.
DB06589
The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Fendiline.
DB06600
The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Fendiline.
DB06603
The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Fendiline.
DB08799
The risk or severity of QTc prolongation can be increased when Antazoline is combined with Fendiline.
DB08865
The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Fendiline.
DB08903
The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Fendiline.
DB09016
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Butriptyline.
DB09078
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Lenvatinib.
DB09555
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Dexchlorpheniramine maleate.
DB11640
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Amifampridine.
DB11830
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Mocetinostat.
DB11841
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Entinostat.
DB12141
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Gilteritinib.
DB12174
The risk or severity of QTc prolongation can be increased when Fendiline is combined with CUDC-101.
DB12376
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Ricolinostat.
DB12523
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Mizolastine.
DB12565
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Abexinostat.
DB12877
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Oxatomide.
DB13261
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Sitafloxacin.
DB13273
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Sultopride.
DB13679
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Dexchlorpheniramine.
DB14568
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Ivosidenib.
DB00321
The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Fendiline.
DB00458
The risk or severity of QTc prolongation can be increased when Imipramine is combined with Fendiline.
DB00976
The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Fendiline.
DB01211
The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Fendiline.
DB01224
The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Fendiline.
DB01227
The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Fendiline.
DB01232
The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Fendiline.
DB01242
The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Fendiline.
DB11718
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Encorafenib.
DB01084
The risk or severity of QTc prolongation can be increased when Emedastine is combined with Fendiline.
DB15982
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Berotralstat.
DB00107
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.
DB00188
The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fendiline.
DB00196
The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fendiline.
DB00245
The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Fendiline.
DB00285
The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Fendiline.
DB00289
The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fendiline.
DB00334
The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Fendiline.
DB00341
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Fendiline.
DB00344
The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Fendiline.
DB00346
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fendiline.
DB00354
The risk or severity of QTc prolongation can be increased when Buclizine is combined with Fendiline.
DB00358
The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Fendiline.
DB00366
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Fendiline.
DB00370
The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Fendiline.
DB00374
The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Fendiline.
DB00398
The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fendiline.
DB00405
The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fendiline.
DB00427
The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Fendiline.
DB00434
The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Fendiline.
DB00467
The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Fendiline.
DB00487
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Fendiline.
DB00529
The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Fendiline.
DB00543
The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Fendiline.
DB00613
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fendiline.
DB00674
The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fendiline.
DB00675
The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Fendiline.
DB00691
The risk or severity of QTc prolongation can be increased when Moexipril is combined with Fendiline.
DB00697
The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Fendiline.
DB00710
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fendiline.
DB00714
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fendiline.
DB00719
The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fendiline.
DB00734
The risk or severity of QTc prolongation can be increased when Risperidone is combined with Fendiline.
DB00753
The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Fendiline.
DB00808
The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fendiline.
DB00817
The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Fendiline.
DB00818
The risk or severity of QTc prolongation can be increased when Propofol is combined with Fendiline.
DB00822
The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Fendiline.
DB00835
The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Fendiline.
DB00871
The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fendiline.
DB00915
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fendiline.
DB00916
The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Fendiline.
DB00920
The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Fendiline.
DB00927
The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fendiline.
DB00934
The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fendiline.
DB00938
The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fendiline.
DB00949
The risk or severity of QTc prolongation can be increased when Felbamate is combined with Fendiline.
DB00983
The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fendiline.
DB00999
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Fendiline.
DB01001
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fendiline.
DB01015
The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Fendiline.
DB01036
The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Fendiline.
DB01044
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Fendiline.
DB01059
The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Fendiline.
DB01069
The risk or severity of QTc prolongation can be increased when Promethazine is combined with Fendiline.
DB01071
The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Fendiline.
DB01075
The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fendiline.
DB01106
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Fendiline.
DB01151
The risk or severity of QTc prolongation can be increased when Desipramine is combined with Fendiline.
DB01166
The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Fendiline.
DB01173
The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Fendiline.
DB01176
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Fendiline.
DB01189
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Fendiline.
DB01233
The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fendiline.
DB01236
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Fendiline.
DB01238
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fendiline.
DB01239
The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Fendiline.
DB01246
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Fendiline.
DB01259
The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Fendiline.
DB01268
The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Fendiline.
DB01274
The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Fendiline.
DB01403
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Fendiline.
DB01591
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Fendiline.
DB01611
The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fendiline.
DB01620
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fendiline.
DB01623
The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fendiline.
DB02546
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Fendiline.
DB04576
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Fendiline.
DB04695
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Fendiline.
DB04953
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Fendiline.
DB05039
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fendiline.
DB05465
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fendiline.
DB06282
The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Fendiline.
DB06288
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Fendiline.
DB06663
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fendiline.
DB06691
The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Fendiline.
DB06699
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fendiline.
DB06719
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Fendiline.
DB06788
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Fendiline.
DB06825
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fendiline.
DB07780
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Fendiline.
DB07841
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Fendiline.
DB08871
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fendiline.
DB08893
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fendiline.
DB08912
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Fendiline.
DB08936
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Fendiline.
DB08972
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fendiline.
DB09080
The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fendiline.
DB09082
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Fendiline.
DB09167
The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Fendiline.
DB09488
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fendiline.
DB11390
The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Fendiline.
DB11397
The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Fendiline.
DB11408
The risk or severity of QTc prolongation can be increased when Famphur is combined with Fendiline.
DB11412
The risk or severity of QTc prolongation can be increased when Fenthion is combined with Fendiline.
DB11443
The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Fendiline.
DB11448
The risk or severity of QTc prolongation can be increased when Phosmet is combined with Fendiline.
DB11491
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Fendiline.
DB11511
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Fendiline.
DB11591
The risk or severity of QTc prolongation can be increased when Bilastine is combined with Fendiline.
DB11614
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Fendiline.
DB11774
The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Fendiline.
DB11891
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Fendiline.
DB11892
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Fendiline.
DB11943
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Fendiline.
DB12231
The risk or severity of QTc prolongation can be increased when Temefos is combined with Fendiline.
DB12245
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Fendiline.
DB12645
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Fendiline.
DB13627
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Fendiline.
DB13744
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Fendiline.
DB13772
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Fendiline.
DB13823
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Fendiline.
DB14185
The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Fendiline.
DB14713
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Fendiline.
DB00220
The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Fendiline.
DB00726
The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Fendiline.
DB00540
The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Fendiline.
DB00582
The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Fendiline.
DB00862
The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Fendiline.
DB01026
The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Fendiline.
DB01072
The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Fendiline.
DB01142
The risk or severity of QTc prolongation can be increased when Doxepin is combined with Fendiline.
DB01167
The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Fendiline.
DB01254
The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fendiline.
DB01263
The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Fendiline.
DB08815
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Fendiline.
DB08864
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fendiline.
DB11742
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fendiline.
DB01601
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Fendiline.
DB00845
The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Fendiline.
DB11796
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Fendiline.
DB00751
The risk or severity of QTc prolongation can be increased when Epinastine is combined with Fendiline.
DB11853
The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fendiline.
DB00211
Midodrine may increase the bradycardic activities of Fendiline.
DB00436
Bendroflumethiazide may increase the bradycardic activities of Fendiline.
DB00633
Dexmedetomidine may increase the bradycardic activities of Fendiline.
DB00899
Remifentanil may increase the bradycardic activities of Fendiline.
DB00968
Methyldopa may increase the bradycardic activities of Fendiline.
DB00989
Rivastigmine may increase the bradycardic activities of Fendiline.
DB04897
Lucinactant may increase the bradycardic activities of Fendiline.
DB06415
Calfactant may increase the bradycardic activities of Fendiline.
DB06761
Beractant may increase the bradycardic activities of Fendiline.
DB06791
Lanreotide may increase the bradycardic activities of Fendiline.
DB09113
Fendiline may increase the bradycardic activities of Poractant alfa.
DB00708
Sufentanil may increase the bradycardic activities of Fendiline.
DB00802
Alfentanil may increase the bradycardic activities of Fendiline.
DB00813
Fentanyl may increase the bradycardic activities of Fendiline.
DB00843
Donepezil may increase the bradycardic activities of Fendiline.
DB01018
Guanfacine may increase the bradycardic activities of Fendiline.
DB06218
Lacosamide may increase the bradycardic activities of Fendiline.
DB08895
Tofacitinib may increase the bradycardic activities of Fendiline.
DB08896
Regorafenib may increase the bradycardic activities of Fendiline.
DB08868
Fingolimod may increase the bradycardic activities of Fendiline.
DB00159
The risk or severity of hyperkalemia can be increased when Icosapent is combined with Fendiline.
DB00177
The risk or severity of hyperkalemia can be increased when Valsartan is combined with Fendiline.
DB00178
The risk or severity of hyperkalemia can be increased when Ramipril is combined with Fendiline.
DB00202
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fendiline.
DB00275
The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Fendiline.
DB00328
The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Fendiline.
DB00384
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Fendiline.
DB00407
The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Fendiline.
DB00421
The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fendiline.
DB00461
The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Fendiline.
DB00465
The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Fendiline.
DB00469
The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Fendiline.
DB00482
The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Fendiline.
DB00492
The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Fendiline.
DB00500
The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Fendiline.
DB00519
The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Fendiline.
DB00533
The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Fendiline.
DB00542
The risk or severity of hyperkalemia can be increased when Benazepril is combined with Fendiline.
DB00554
The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Fendiline.
DB00573
The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Fendiline.
DB00580
The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Fendiline.
DB00584
The risk or severity of hyperkalemia can be increased when Enalapril is combined with Fendiline.
DB00586
The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Fendiline.
DB00594
The risk or severity of hyperkalemia can be increased when Amiloride is combined with Fendiline.
DB00605
The risk or severity of hyperkalemia can be increased when Sulindac is combined with Fendiline.
DB00698
The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Fendiline.
DB00712
The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Fendiline.
DB00722
The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Fendiline.
DB00742
The risk or severity of hyperkalemia can be increased when Mannitol is combined with Fendiline.
DB00749
The risk or severity of hyperkalemia can be increased when Etodolac is combined with Fendiline.
DB00784
The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Fendiline.
DB00788
The risk or severity of hyperkalemia can be increased when Naproxen is combined with Fendiline.
DB00790
The risk or severity of hyperkalemia can be increased when Perindopril is combined with Fendiline.
DB00796
The risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Fendiline.
DB00812
The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Fendiline.
DB00814
The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Fendiline.
DB00821
The risk or severity of hyperkalemia can be increased when Carprofen is combined with Fendiline.
DB00876
The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Fendiline.
DB00881
The risk or severity of hyperkalemia can be increased when Quinapril is combined with Fendiline.
DB00886
The risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Fendiline.
DB00939
The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Fendiline.
DB00966
The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Fendiline.
DB00991
The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Fendiline.
DB01009
The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Fendiline.
DB01029
The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Fendiline.
DB01050
The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Fendiline.
DB01109
The risk or severity of hyperkalemia can be increased when Heparin is combined with Fendiline.
DB01180
The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Fendiline.
DB01197
The risk or severity of hyperkalemia can be increased when Captopril is combined with Fendiline.
DB01225
The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Fendiline.
DB01283
The risk or severity of hyperkalemia can be increased when Lumiracoxib is combined with Fendiline.
DB01340
The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Fendiline.
DB01342
The risk or severity of hyperkalemia can be increased when Forasartan is combined with Fendiline.
DB01347
The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Fendiline.
DB01348
The risk or severity of hyperkalemia can be increased when Spirapril is combined with Fendiline.
DB01349
The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Fendiline.
DB01395
The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Fendiline.
DB01399
The risk or severity of hyperkalemia can be increased when Salsalate is combined with Fendiline.
DB01401
The risk or severity of hyperkalemia can be increased when Choline magnesium trisalicylate is combined with Fendiline.
DB01419
The risk or severity of hyperkalemia can be increased when Antrafenine is combined with Fendiline.
DB01424
The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Fendiline.
DB01435
The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Fendiline.
DB01600
The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Fendiline.
DB01628
The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Fendiline.
DB02968
The risk or severity of hyperkalemia can be increased when Penicillin G Acyl-Serine is combined with Fendiline.
DB03585
The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Fendiline.
DB04812
The risk or severity of hyperkalemia can be increased when Benoxaprofen is combined with Fendiline.
DB04817
The risk or severity of hyperkalemia can be increased when Metamizole is combined with Fendiline.
DB04828
The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Fendiline.
DB05095
The risk or severity of hyperkalemia can be increased when Cimicoxib is combined with Fendiline.
DB06271
The risk or severity of hyperkalemia can be increased when Sulodexide is combined with Fendiline.
DB06725
The risk or severity of hyperkalemia can be increased when Lornoxicam is combined with Fendiline.
DB06736
The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Fendiline.
DB06737
The risk or severity of hyperkalemia can be increased when Zaltoprofen is combined with Fendiline.
DB06754
The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Fendiline.
DB06763
The risk or severity of hyperkalemia can be increased when Saralasin is combined with Fendiline.
DB06767
The risk or severity of hyperkalemia can be increased when Ammonium chloride is combined with Fendiline.
DB06779
The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Fendiline.
DB06822
The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Fendiline.
DB07402
The risk or severity of hyperkalemia can be increased when Azapropazone is combined with Fendiline.
DB08439
The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Fendiline.
DB08797
The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Fendiline.
DB08813
The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Fendiline.
DB08822
The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Fendiline.
DB08836
The risk or severity of hyperkalemia can be increased when Temocapril is combined with Fendiline.
DB08940
The risk or severity of hyperkalemia can be increased when Kebuzone is combined with Fendiline.
DB08942
The risk or severity of hyperkalemia can be increased when Isoxicam is combined with Fendiline.
DB08951
The risk or severity of hyperkalemia can be increased when Indoprofen is combined with Fendiline.
DB08955
The risk or severity of hyperkalemia can be increased when Ibuproxam is combined with Fendiline.
DB08976
The risk or severity of hyperkalemia can be increased when Floctafenine is combined with Fendiline.
DB08981
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Fenbufen.
DB08984
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Etofenamate.
DB08991
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Epirizole.
DB09015
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Canrenoic acid.
DB09026
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Aliskiren.
DB09084
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Benzydamine.
DB09213
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Dexibuprofen.
DB09214
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Dexketoprofen.
DB09215
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Droxicam.
DB09217
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Firocoxib.
DB09218
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Clonixin.
DB09258
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Bemiparin.
DB09259
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Reviparin.
DB09260
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Parnaparin.
DB09261
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Certoparin.
DB09279
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Fimasartan.
DB09285
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Morniflumate.
DB09288
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Propacetamol.
DB09295
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Talniflumate.
DB09477
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Enalaprilat.
DB11455
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Robenacoxib.
DB11466
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Tepoxalin.
DB11518
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Flunixin.
DB11783
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Imidapril.
DB12097
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Mannitol busulfan.
DB12221
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Canrenone.
DB12545
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Indobufen.
DB13001
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Tinoridine.
DB13166
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Zofenopril.
DB13167
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Alclofenac.
DB13217
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Fentiazac.
DB13232
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Suxibuzone.
DB13286
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Bumadizone.
DB13312
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Delapril.
DB13314
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Alminoprofen.
DB13371
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Difenpiramide.
DB13407
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Nifenazone.
DB13432
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Lonazolac.
DB13481
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Tenidap.
DB13524
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Propyphenazone.
DB13527
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Proglumetacin.
DB13544
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Ethenzamide.
DB13629
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Mofebutazone.
DB13649
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Proquazone.
DB13657
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Benorilate.
DB13722
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Pirprofen.
DB13783
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Acemetacin.
DB13860
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Imidazole salicylate.
DB13919
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Candesartan.
DB14059
The risk or severity of hyperkalemia can be increased when Fendiline is combined with SC-236.
DB14060
The risk or severity of hyperkalemia can be increased when Fendiline is combined with NS-398.
DB14125
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Benazeprilat.
DB14208
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Ramiprilat.
DB14213
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Perindoprilat.
DB14217
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Quinaprilat.
DB00091
The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fendiline.
DB00244
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fendiline.
DB00700
The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Fendiline.
DB00795
The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Fendiline.
DB00861
The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Fendiline.
DB00936
The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Fendiline.
DB00945
The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fendiline.
DB01014
The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Fendiline.
DB01250
The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Fendiline.
DB06212
The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Fendiline.
DB12445
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Nitroaspirin.
DB13538
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Guacetisal.
DB13612
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Carbaspirin calcium.
DB00440
The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fendiline.
DB09212
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Loxoprofen.
DB09204
The risk or severity of hypotension can be increased when Arotinolol is combined with Fendiline.
DB06395
The therapeutic efficacy of Abafungin can be increased when used in combination with Fendiline.
DB06440
The therapeutic efficacy of Ravuconazole can be increased when used in combination with Fendiline.
DB12073
The therapeutic efficacy of Albaconazole can be increased when used in combination with Fendiline.
DB01110
The therapeutic efficacy of Miconazole can be increased when used in combination with Fendiline.
DB06636
The therapeutic efficacy of Isavuconazonium can be increased when used in combination with Fendiline.
DB11633
The therapeutic efficacy of Isavuconazole can be increased when used in combination with Fendiline.
DB04794
The therapeutic efficacy of Bifonazole can be increased when used in combination with Fendiline.
DB11637
Fendiline may increase the QTc-prolonging activities of Delamanid.
DB11642
The serum concentration of Fendiline can be decreased when it is combined with Pitolisant.
DB13967
The therapeutic efficacy of Fendiline can be decreased when used in combination with Patent Blue.
DB00681
Fendiline may decrease the nephrotoxic activities of Amphotericin B.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Fendiline.
DB01046
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fendiline.
DB01079
The therapeutic efficacy of Tegaserod can be decreased when used in combination with Fendiline.
DB01378
The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Fendiline.
DB01593
The therapeutic efficacy of Zinc can be decreased when used in combination with Fendiline.
DB01638
The therapeutic efficacy of Sorbitol can be decreased when used in combination with Fendiline.
DB04816
The therapeutic efficacy of Dantron can be decreased when used in combination with Fendiline.
DB04823
The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Fendiline.
DB04824
The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Fendiline.
DB07715
The therapeutic efficacy of Emodin can be decreased when used in combination with Fendiline.
DB08890
The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fendiline.
DB09020
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Fendiline.
DB09219
The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Fendiline.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fendiline.
DB09287
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fendiline.
DB09311
The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Fendiline.
DB09409
The therapeutic efficacy of Magnesium acetate tetrahydrate can be decreased when used in combination with Fendiline.
DB09462
The therapeutic efficacy of Glycerin can be decreased when used in combination with Fendiline.
DB09472
The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Fendiline.
DB09484
The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Fendiline.
DB11057
The therapeutic efficacy of Mineral oil can be decreased when used in combination with Fendiline.
DB11059
The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Fendiline.
DB11089
The therapeutic efficacy of Docusate can be decreased when used in combination with Fendiline.
DB11097
The therapeutic efficacy of Plantago seed can be decreased when used in combination with Fendiline.
DB11113
The therapeutic efficacy of Castor oil can be decreased when used in combination with Fendiline.
DB11189
The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Fendiline.
DB11228
The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Fendiline.
DB11365
The therapeutic efficacy of Sennosides can be decreased when used in combination with Fendiline.
DB12942
The therapeutic efficacy of Lactitol can be decreased when used in combination with Fendiline.
DB13170
The therapeutic efficacy of Plecanatide can be decreased when used in combination with Fendiline.
DB13180
The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Fendiline.
DB13526
The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Fendiline.
DB13707
The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Fendiline.
DB13996
The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Fendiline.
DB14232
The therapeutic efficacy of Deacetylbisacodyl can be decreased when used in combination with Fendiline.
DB14482
The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Fendiline.
DB14502
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fendiline.
DB14503
The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Fendiline.
DB14504
The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Fendiline.
DB14516
The therapeutic efficacy of Sodium cation can be decreased when used in combination with Fendiline.
DB14585
The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Fendiline.
DB14627
The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Fendiline.
DB14684
The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Fendiline.
DB14963
The therapeutic efficacy of Konjac mannan can be decreased when used in combination with Fendiline.
DB15477
The therapeutic efficacy of Alloin can be decreased when used in combination with Fendiline.
DB15478
The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Fendiline.
DB11622
The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Fendiline.
DB06480
The therapeutic efficacy of Prucalopride can be decreased when used in combination with Fendiline.
DB14546
The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Fendiline.
DB09046
The metabolism of Fendiline can be increased when combined with Metreleptin.
DB00761
Potassium chloride may increase the hyperkalemic activities of Fendiline.
DB09125
Fendiline may increase the hyperkalemic activities of Potassium citrate.
DB11098
Fendiline may increase the hyperkalemic activities of Potassium bicarbonate.
DB14498
Fendiline may increase the hyperkalemic activities of Potassium acetate.
DB09087
Potassium alum may increase the hyperkalemic activities of Fendiline.
DB09418
Potassium perchlorate may increase the hyperkalemic activities of Fendiline.
DB11107
Potassium bitartrate may increase the hyperkalemic activities of Fendiline.
DB13620
Potassium gluconate may increase the hyperkalemic activities of Fendiline.
DB13831
Potassium permanganate may increase the hyperkalemic activities of Fendiline.
DB13977
Potassium carbonate may increase the hyperkalemic activities of Fendiline.
DB14492
Potassium triiodide may increase the hyperkalemic activities of Fendiline.
DB14500
Potassium may increase the hyperkalemic activities of Fendiline.
DB09413
Fendiline may increase the hyperkalemic activities of Monopotassium phosphate.
DB09414
Fendiline may increase the hyperkalemic activities of Dipotassium phosphate.
DB09449
Fendiline may increase the hyperkalemic activities of Sodium phosphate, monobasic.
DB09483
Fendiline may increase the hyperkalemic activities of Potassium lactate.
DB14499
Fendiline may increase the hyperkalemic activities of Potassium sulfate.
DB06715
Potassium Iodide may increase the hyperkalemic activities of Fendiline.
DB11090
Potassium nitrate may increase the hyperkalemic activities of Fendiline.
DB11153
Potassium hydroxide may increase the hyperkalemic activities of Fendiline.
DB13735
Potassium guaiacolsulfonate may increase the hyperkalemic activities of Fendiline.
DB01345
Potassium cation may increase the hyperkalemic activities of Fendiline.
DB08907
The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fendiline.
DB00030
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin human.
DB00046
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin lispro.
DB00047
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin glargine.
DB00071
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin pork.
DB00284
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Acarbose.
DB00331
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Metformin.
DB00414
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Acetohexamide.
DB00491
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Miglitol.
DB00672
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Chlorpropamide.
DB00839
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Tolazamide.
DB00914
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Phenformin.
DB01120
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Gliclazide.
DB01124
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Tolbutamide.
DB01251
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Gliquidone.
DB01252
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Mitiglinide.
DB01276
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Exenatide.
DB01277
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Mecasermin.
DB01278
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Pramlintide.
DB01289
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Glisoxepide.
DB01306
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin aspart.
DB01307
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin detemir.
DB01309
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin glulisine.
DB01382
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Glymidine.
DB01700
The risk or severity of hypoglycemia can be increased when Fendiline is combined with AICA ribonucleotide.
DB04830
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Buformin.
DB04876
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Vildagliptin.
DB04878
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Voglibose.
DB05115
The risk or severity of hypoglycemia can be increased when Fendiline is combined with NN344.
DB05819
The risk or severity of hypoglycemia can be increased when Fendiline is combined with NBI-6024.
DB06011
The risk or severity of hypoglycemia can be increased when Fendiline is combined with AMG-222.
DB06127
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Bisegliptin.
DB06655
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Liraglutide.
DB08382
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Gosogliptin.
DB08962
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Glibornuride.
DB09022
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Benfluorex.
DB09038
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Empagliflozin.
DB09043
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Albiglutide.
DB09045
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Dulaglutide.
DB09265
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Lixisenatide.
DB09456
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin beef.
DB09564
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin degludec.
DB11567
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin peglispro.
DB11568
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin tregopil.
DB11698
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Ipragliflozin.
DB11723
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Dutogliptin.
DB11780
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Allicin.
DB11824
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Tofogliflozin.
DB11827
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Ertugliflozin.
DB11898
The risk or severity of hypoglycemia can be increased when Fendiline is combined with 2,4-thiazolidinedione.
DB11950
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Teneligliptin.
DB11992
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Omarigliptin.
DB12268
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Carmegliptin.
DB12412
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Gemigliptin.
DB12417
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Anagliptin.
DB12625
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Evogliptin.
DB12713
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Sotagliflozin.
DB12935
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Remogliflozin etabonate.
DB13406
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Carbutamide.
DB13446
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Guar gum.
DB13675
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Metahexamide.
DB13928
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Semaglutide.
DB14027
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Taspoglutide.
DB14035
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Englitazone.
DB15171
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Tirzepatide.
DB15217
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Gastric inhibitory polypeptide.
DB01067
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Glipizide.
DB00197
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Troglitazone.
DB00359
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Sulfadiazine.
DB00412
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Rosiglitazone.
DB00731
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Nateglinide.
DB00912
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Repaglinide.
DB01016
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Glyburide.
DB01132
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Pioglitazone.
DB01261
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Sitagliptin.
DB06203
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Alogliptin.
DB06292
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Dapagliflozin.
DB06335
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Saxagliptin.
DB08882
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Linagliptin.
DB09198
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Lobeglitazone.
DB09199
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Netoglitazone.
DB09200
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Rivoglitazone.
DB09201
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Ciglitazone.
DB12781
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Balaglitazone.
DB00373
The risk or severity of adverse effects can be increased when Fendiline is combined with Timolol.
DB00612
The therapeutic efficacy of Fendiline can be increased when used in combination with Bisoprolol.
DB00575
Clonidine may increase the atrioventricular blocking (AV block) activities of Fendiline.
DB00656
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fendiline.
DB11986
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Entrectinib.
DB12825
Lefamulin may increase the QTc-prolonging activities of Fendiline.
DB11732
Lasmiditan may increase the bradycardic activities of Fendiline.
DB00388
The risk or severity of hypertension can be decreased when Fendiline is combined with Phenylephrine.
DB06119
The serum concentration of Fendiline can be decreased when it is combined with Cenobamate.
DB00557
The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Fendiline.
DB01118
The risk or severity of adverse effects can be increased when Fendiline is combined with Amiodarone.
DB00864
Tacrolimus may increase the immunosuppressive activities of Fendiline.
DB00877
Fendiline may increase the immunosuppressive activities of Sirolimus.
DB01020
Fendiline may increase the vasodilatory activities of Isosorbide mononitrate.
DB00727
Fendiline may increase the vasodilatory activities of Nitroglycerin.
DB00883
Fendiline may increase the vasodilatory activities of Isosorbide dinitrate.
DB01612
Fendiline may increase the vasodilatory activities of Amyl Nitrite.
DB01613
Fendiline may increase the vasodilatory activities of Erythrityl tetranitrate.
DB06154
Fendiline may increase the vasodilatory activities of Pentaerythritol tetranitrate.
DB09401
Fendiline may increase the vasodilatory activities of Isosorbide.
DB13255
Fendiline may increase the vasodilatory activities of Propatyl nitrate.
DB13408
Fendiline may increase the vasodilatory activities of Methylpropylpropanediol dinitrate.
DB13637
Fendiline may increase the vasodilatory activities of Tenitramine.
DB13719
Fendiline may increase the vasodilatory activities of Trolnitrate.
DB14049
Fendiline may increase the vasodilatory activities of Nitrate.
DB00246
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Ziprasidone.
DB01264
The serum concentration of Fendiline can be increased when it is combined with Darunavir.
DB14513
Fendiline can cause a decrease in the absorption of Magnesium resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00503
The serum concentration of Fendiline can be increased when it is combined with Ritonavir.
DB00502
The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Fendiline.
DB11652
The metabolism of Tucatinib can be decreased when combined with Fendiline.
DB00472
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Fluoxetine.
DB00104
The serum concentration of the active metabolites of Fendiline can be increased when Fendiline is used in combination with Octreotide.
DB11932
The serum concentration of Fendiline can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Fendiline can be decreased when it is combined with Satralizumab.

序列

实验性质

Melting Point
200-201
U.S. Patent 3,262,977.

外部标识符

resource：ChEBI
identifier：94434
resource：PubChem Compound
identifier：3336
resource：PubChem Substance
identifier：310264941
resource：KEGG Drug
identifier：D07185
resource：ChemSpider
identifier：3219
resource：BindingDB
identifier：61401
resource：Wikipedia
identifier：Fendiline
resource：ChEMBL
identifier：CHEMBL254832
resource：RxCUI
identifier：4327

外部链接

路径

目标

酶

BE0002638Cytochrome P450 3A4HumanssubstrateA3627122039822Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.noCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic process

载体

运输工具

药物反应

效应

不良反应